GenScript Upgrades Plasmid Production Platform to Deliver Potent Plasmids

Piscataway, NJ, August 07, 2009 --(PR.com)-- International life science contract research organization (CRO) GenScript USA Inc. has upgraded its plasmid preparation platform with an intention to better serve their customers’ needs for demanding downstream applications. The upgrade produces premium plasmids for high efficient transfection, smooth DNA vaccination, and antibody production.

GenScript’s new plasmid grades as a result of the upgrade are highly supercoiled (SC ≥ 95% for SC Grade and Advanced SC Grade) with ultra-low levels of endotoxin (≤ 0.005 EU/μg for Advanced SC Grade). The upgrade includes rigorous quality control and complete enzyme-free plasmid production process. In addition, DNA shearing is minimized to ensure plasmid integrity and its suitability for standard downstream applications without requirement for further manipulation.

GenScript’s gene services ranges from gene synthesis, cloning, to advanced engineering and library construction. To date, the company holds a record of having synthesized over one hundred thousand genes, including genes of over 50,000 bp in length and numbers of complex genes.

GenScript is a contract research organization (CRO) specialized in biological research and drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bio-reagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has become a world-leading Biology CRO and the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China.

###